Myriad Genetics推出了其下一代的分子诊断工具myRisk Hereditary Cancer多基因诊断测试

  

Myriad Genetics推出了其下一代的分子诊断工具myRisk Hereditary Cancer多基因诊断测试，可以检测与8种主要癌症（乳腺癌，大肠癌，卵巢癌，子宫内膜癌，胰腺癌，前列腺癌，胃癌和黑色素瘤）相关的25个不同基因。患者需为检测自负100美元不到，与检测两个基因的BRACAnalysis相当。

 

Myriad Genetics Launches myRisk(TM) Hereditary Cancer Panel

Early Access Program Underway With Select Healthcare Providers

SALT LAKE CITY, Sept. 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has launched myRisk Hereditary Cancer, a new multi-gene diagnostic test that will provide increased sensitivity by analyzing 25 genes associated with eight major cancers including: breast, colorectal, ovarian, endometrial, pancreatic, prostate, gastric and melanoma.

"We are excited to launch myRisk Hereditary Cancer, which is a significant scientific advancement in hereditary cancer testing for a range of clinically-actionable cancers," said Mark Capone, president of Myriad Genetics Laboratories. "myRisk Hereditary Cancer will improve the quality of patient care by empowering healthcare providers with knowledge about their patients' risk of hereditary cancer and the appropriate medical management options available based on that risk."

myRisk Hereditary Cancer is being launched in a phased approach beginning with an early-access, clinical-experience program to a limited number of medical and scientific thought leaders followed by an expanded access program later in the year. The Company will present extensive clinical validity data for myRisk Hereditary Cancer at The Collaborative Group of the Americas on Inherited Colorectal Cancer (CGA) annual meeting in October and the San Antonio Breast Cancer Symposium in December.

The new myRisk Hereditary Cancer test represents the next generation of hereditary cancer testing and will provide healthcare providers with clear and actionable information to improve patient care, regardless of whether the patient receives a positive or negative test result. Each test report will include a genetic test result, a clinical risk and healthcare management tool based on professional society guidelines.

"Myriad is taking a stepwise, careful approach to responsibly gather clinical experience with the myRisk Hereditary Cancer test before fully launching this potentially revolutionary new diagnostic test for hereditary cancer," said  Lee S. Schwartzberg, M.D., chief, Division of Hematology and Oncology at the University of Tennessee Health Science Center.  "Myriad's unparalleled experience bolstered by extensive clinical research provides the reassurance healthcare providers require to utilize new methods of hereditary cancer testing. Also, the breadth of Myriad's new test report should empower medical professionals with the right information to facilitate better education and counselling for their patients."

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.

Myriad, the Myriad logo and BRACAnalysis, myRisk, myRisk Hereditary Cancer, and Myriad Practice Advisor are trademarks or registered trademarks of Myriad Genetics, Inc. inthe United States and foreign countries. MYGN-F, MYGN-G